Tempus

Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus

Retrieved on: 
金曜日, 5月 31, 2024
Research, Public Relations, Investor Relations, Genetics, Communications, Health, General Health, Other Science, Science, Oncology, Genomics, Patient, DNA, NeXT, Recurrence, Breast cancer, MRD, Blood, Cancer, ASCO, Society, Breast, Immunotherapy, Physician, Tempus, Annual general meeting, PSNL, Medical imaging

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the commencement of commercialization efforts by Tempus for NeXT Personal® , Personalis’ ultra-sensitive, whole genome-based liquid biopsy assay for detection of minimal residual disease (MRD) and recurrence in cancer.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the commencement of commercialization efforts by Tempus for NeXT Personal® , Personalis’ ultra-sensitive, whole genome-based liquid biopsy assay for detection of minimal residual disease (MRD) and recurrence in cancer.
  • Members of Tempus’ commercial team can now engage in discussions with doctors about the use of the NeXT Personal Dx test for breast and lung cancers, and for immunotherapy monitoring across all solid tumors.
  • “Today’s announcement opens up new possibilities for cancer patients and we’re excited to be working with Tempus to reach oncologists through our collective efforts,” said Chris Hall, CEO, Personalis.
  • The ultra-sensitive, personalized MRD assay identifies up to 1,800 somatic variants unique to each patient’s tumor, supporting physicians in making informed, individualized management decisions for patients.

Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results

Retrieved on: 
木曜日, 5月 9, 2024
AXIN1, Research, Partnership, Clostridioides difficile infection, Development, IND, DeepMind, NVIDIA, Biomarker, Drug discovery, Tempus, Pharmacokinetics, Map, ADME, Machine learning, Software, Appetite, Roche, APC, Infection, Neurofibromatosis type II, CCM, Transcriptome, Safety, Johnson & Johnson, Neuroscience, RNA, Artificial intelligence, FAP, Data science, Therapy, Translation, Chemistry, RBM39, Biology, Clinical trial, LILAC, NF2, University of Oxford, Recurrence, Computational biology, Hemangioma, Administration, Patient, Strategy, Trial of the century, Pharmaceutical industry

L(earnings) Call: Recursion will host a L(earnings) Call on May 9, 2024 at 5:00 pm Eastern Time / 3:00 pm Mountain Time.

Key Points: 
  • L(earnings) Call: Recursion will host a L(earnings) Call on May 9, 2024 at 5:00 pm Eastern Time / 3:00 pm Mountain Time.
  • Revenue: Total revenue was $13.8 million for the first quarter of 2024, compared to $12.1 million for the first quarter of 2023.
  • Research and Development Expenses: Research and development expenses were $67.6 million for the first quarter of 2024, compared to $46.7 million for the first quarter of 2023.
  • Net Loss: Net loss was $91.4 million for the first quarter of 2024, compared to a net loss of $65.3 million for the first quarter of 2023.

Global $46.7B Cancer Biomarkers Market Outlook, 2035: MET Biomarkers Lead the Charge, Driven by Rising Incidence of Lung Cancer and Drug Development - ResearchAndMarkets.com

Retrieved on: 
水曜日, 5月 8, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Foundation Medicine, MSI, Lung cancer, Breast cancer, Blood, AI, MDPI, Skin cancer, Agilent Technologies, Prostate cancer, Biomarker, ALK, Kidney cancer, EGFR, OncoDNA, Cancer, Bladder cancer, Tempus, Son, Non-small-cell lung cancer, Frontiers Media, HER2, Colorectal cancer, Turbine, Thyroid cancer, ARUP Laboratories, Roche, Database, Therapy, Merck, NSCLC, Thermo Fisher Scientific, Nature, Publication, Laboratory, Survival, Insurance, BioMed Central, Nature Portfolio, Incidence, Drug development, Liver cancer, Liquid biopsy, MET, NTRK, CK Life Sciences, Endometrial cancer, Actuate, PD-L1, Patient, Gastrointestinal cancer, Physician, Neoplasm, Head, Medical imaging

Based on the type of cancer, the cancer biomarkers market is segmented into Breast Cancer, Prostate Cancer, Colorectum Cancer, Lung Cancer, Thyroid Cancer, Bladder Cancer, Melanoma, Non-Hodgkins Lymphoma, Endometrial Cancer, Kidney Cancer and Leukemia.

Key Points: 
  • Based on the type of cancer, the cancer biomarkers market is segmented into Breast Cancer, Prostate Cancer, Colorectum Cancer, Lung Cancer, Thyroid Cancer, Bladder Cancer, Melanoma, Non-Hodgkins Lymphoma, Endometrial Cancer, Kidney Cancer and Leukemia.
  • Currently, the market is driven by breast cancer biomarkers and lung cancer biomarkers; however, in the coming future, we anticipate cancer biomarker market for leukemia to grow at a significant pace.
  • The market report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the companies involved in the cancer biomarkers market.
  • It is worth mentioning that Merck is conducting the maximum number of trials in this industry for various cancer indications, including bladder cancer, breast cancer, colorectal cancer, gastrointestinal cancer, gynecological cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, prostate cancer and skin cancer.

GeneCentric Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
月曜日, 4月 1, 2024
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Tempus, Survival, Colorectal cancer, Patient, RNA, MSI, FOLFIRINOX, PDAC, Medicine, Section 42, News, AACR, Microsatellite instability, Therapy, Cancer

GeneCentric Therapeutics , a company making precision medicine more precise through RNA-based diagnostics, today announced upcoming presentations at the American Association for Cancer Research Annual Meeting 2024 being held in San Diego, California from April 5-10.

Key Points: 
  • GeneCentric Therapeutics , a company making precision medicine more precise through RNA-based diagnostics, today announced upcoming presentations at the American Association for Cancer Research Annual Meeting 2024 being held in San Diego, California from April 5-10.
  • Presentations will include a poster describing a new colorectal cancer predictive response signature (MSS-PRS) that selects tumors not identified with conventional MSI testing but have molecular characteristics consistent with microsatellite instability, making them a potential target for immune checkpoint inhibition.
  • A second poster presentation describes ongoing clinical validation for PurISTSM, a novel RNA-expression test developed in collaboration with Tempus.
  • Details of the AACR presentations are as follows:
    Session: PO.CL01.01 – Diagnostic Biomarkers 1, Section 42
    The posters will be accessible under the News & Events section of the Company’s website following the conference.

Personalis Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
水曜日, 2月 28, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, PSNL, Neoplasm, Immunotherapy, Investment, DX, Lung, LDT, NeXT, Medicare, Tempus, MRD, Genomics, Partnership, Video game

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights.
  • “Our efforts in 2024 continue to be focused on executing our Win-in-MRD strategy for NeXT Personal.
  • The conference call can be accessed live by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers.
  • A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.

Global Respiratory Infection Diagnostic Market Research Report 2024-2028 with Executive and Consultant Guides - ResearchAndMarkets.com

Retrieved on: 
水曜日, 2月 28, 2024
Infectious Diseases, Health, Medical Supplies, Medical Devices, Shift, COVID-19, SARS-CoV-2, Tempus

5.26 QuantuMDx Developing Multiplex System, Syndromic Panels

Key Points: 

5.26 QuantuMDx Developing Multiplex System, Syndromic Panels
5.39 Tempus Announces COVID-19 Testing, Data Initiative
5.42 Companies Shift to Multiplex Tests for SARS-CoV-2, Influenza
5.43 Novacyt Gets CE Mark for Coronavirus, Flu, RSV Combo Panel

Experienced Legal and Computer Engineering Expert Jennifer Davis Brings Important Perspectives to Scrum Alliance® Board of Directors

Retrieved on: 
月曜日, 2月 26, 2024
Education, Training, Continuing, New York Law School, IBM, Growth, University, Medicine, Tempus, Teaching, Privacy, Management

Jennifer Davis offers a trio of unique experiences in her new role as a Scrum Alliance board member: she’s an accomplished lawyer who has worked with agile coaches and also holds a computer engineering degree.

Key Points: 
  • Jennifer Davis offers a trio of unique experiences in her new role as a Scrum Alliance board member: she’s an accomplished lawyer who has worked with agile coaches and also holds a computer engineering degree.
  • Davis is associate general counsel for Tempus, a precision medicine company, and previously served in roles at IBM and Spotify.
  • The Scrum Alliance Board of Directors has a minimum of nine members.
  • Of these, three are elected by Scrum Alliance members and referred to as Scrum Certified Member Directors.

Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance

Retrieved on: 
金曜日, 1月 5, 2024
Technology, Medical Devices, Health Technology, Software, Biotechnology, Internet, Health, Data Management, Oncology, Partnership, MRD, System, PSNL, Bank statement, Tempus, MVP, Genomics, Investment

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2023.
  • “To touch on a few highlights, over this past year we launched our NeXT Personal Dx ultrasensitive MRD product, deepened clinical evidence to support obtaining reimbursement, presented unprecedented clinical evidence for early-stage lung cancer detection at medical conferences, expanded our relationships with research collaborators, and forged a new strategic commercial partnership with Tempus to commercialize and ramp our MRD product, all while reducing our annualized expenses by $35 million.
  • I’m very proud of our progress and we expect to further leverage our clinical and commercial strength to drive more success in 2024.”
    The above information is preliminary and subject to Personalis’ normal quarter and year-end accounting procedures and external audit by the company's independent registered public accounting firm.
  • In addition, these preliminary unaudited results are not a comprehensive statement of the company’s financial results for the year ended December 31, 2023, should not be viewed as a substitute for full, audited financial statements prepared in accordance with generally accepted accounting principles, and are not necessarily indicative of the company’s results for any future period.

Biotech Veteran Marc Yoskowitz Named Evozyne CEO

Retrieved on: 
木曜日, 1月 4, 2024
Professional Services, Health, Technology, Finance, General Health, Artificial Intelligence, Biotechnology, Paragon, Pfizer, McKinsey & Company, Drug discovery, Protein, OrbiMed, Hospira, Tempus, Patient, NVIDIA

Chicago-based Evozyne today announced Marc Yoskowitz as CEO of the generative AI-driven biotech.

Key Points: 
  • Chicago-based Evozyne today announced Marc Yoskowitz as CEO of the generative AI-driven biotech.
  • Yoskowitz has held executive leadership positions with Pfizer, Hospira and McKinsey & Company, bringing deep biopharmaceutical, corporate development and strategy expertise to the role.
  • Leading a company that is pioneering this technology and developing novel proteins is an unparalleled opportunity,” Yoskowitz said.
  • Founded in 2020 by Paragon Biosciences, Evozyne develops novel proteins that solve high-impact problems in human health.

Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives

Retrieved on: 
月曜日, 12月 4, 2023
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Marketing, Medicare, NeXT, Genomics, Patient, PSNL, MRD, Pharmaceutical industry, Chief Justice of Hungary, Tempus

Personalis, Inc. , a leader in advanced genomics for precision oncology (Nasdaq: PSNL), disclosed a reduction in headcount impacting approximately 20% of the company’s staff.

Key Points: 
  • Personalis, Inc. , a leader in advanced genomics for precision oncology (Nasdaq: PSNL), disclosed a reduction in headcount impacting approximately 20% of the company’s staff.
  • By consolidating several functions for efficiency, this reduction is expected to reduce operating expenses by approximately $14 million annually.
  • This action, along with the recently announced Tempus collaboration , is expected to extend the cash position of the company into 2026.
  • “Continuing to optimize our resources, as well as building new relationships, have been goals for us this year as we position Personalis to be a clinical testing leader,” stated Chris Hall, President and CEO of Personalis.